TY - JOUR
T1 - EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3
AU - Guedj, Eric
AU - Varrone, Andrea
AU - Boellaard, Ronald
AU - Albert, Nathalie L
AU - Barthel, Henryk
AU - van Berckel, Bart
AU - Brendel, Matthias
AU - Cecchin, Diego
AU - Ekmekcioglu, Ozgul
AU - Garibotto, Valentina
AU - Lammertsma, Adriaan A
AU - Law, Ian
AU - Peñuelas, Iván
AU - Semah, Franck
AU - Traub-Weidinger, Tatjana
AU - van de Giessen, Elsmarieke
AU - Van Weehaeghe, Donatienne
AU - Morbelli, Silvia
N1 - © 2021. The Author(s).
PY - 2022/1
Y1 - 2022/1
N2 - The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [18F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations.
AB - The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [18F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations.
KW - Brain/diagnostic imaging
KW - Fluorodeoxyglucose F18/metabolism
KW - Humans
KW - Nuclear Medicine
KW - Positron-Emission Tomography
KW - Tomography, X-Ray Computed
UR - http://www.scopus.com/inward/record.url?scp=85120900330&partnerID=8YFLogxK
U2 - 10.1007/s00259-021-05603-w
DO - 10.1007/s00259-021-05603-w
M3 - Journal article
C2 - 34882261
SN - 1619-7070
VL - 49
SP - 632
EP - 651
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 2
ER -